Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR) : tumor expression patterns and prognostic value in oral cancer. / Christensen, Anders; Kiss, Katalin; Lelkaitis, Giedrius; Juhl, Karina; Persson, Morten; Charabi, Birgitte Wittenborg; Mortensen, Jann; Forman, Julie Lyng; Sørensen, Anne Lyngholm; Jensen, David Hebbelstrup; Kjaer, Andreas; von Buchwald, Christian.

I: BMC Cancer, Bind 17, 572, 2017.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Christensen, A, Kiss, K, Lelkaitis, G, Juhl, K, Persson, M, Charabi, BW, Mortensen, J, Forman, JL, Sørensen, AL, Jensen, DH, Kjaer, A & von Buchwald, C 2017, 'Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer', BMC Cancer, bind 17, 572. https://doi.org/10.1186/s12885-017-3563-3

APA

Christensen, A., Kiss, K., Lelkaitis, G., Juhl, K., Persson, M., Charabi, B. W., ... von Buchwald, C. (2017). Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer, 17, [572]. https://doi.org/10.1186/s12885-017-3563-3

Vancouver

Christensen A, Kiss K, Lelkaitis G, Juhl K, Persson M, Charabi BW o.a. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer. 2017;17. 572. https://doi.org/10.1186/s12885-017-3563-3

Author

Christensen, Anders ; Kiss, Katalin ; Lelkaitis, Giedrius ; Juhl, Karina ; Persson, Morten ; Charabi, Birgitte Wittenborg ; Mortensen, Jann ; Forman, Julie Lyng ; Sørensen, Anne Lyngholm ; Jensen, David Hebbelstrup ; Kjaer, Andreas ; von Buchwald, Christian. / Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR) : tumor expression patterns and prognostic value in oral cancer. I: BMC Cancer. 2017 ; Bind 17.

Bibtex

@article{91af0b0e8a464710b35aec0b279d6bba,
title = "Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer",
abstract = "Background: Tumor-specific biomarkers are a prerequisite for the development of targeted imaging and therapy in oral squamous cell carcinoma (OSCC). urokinase-type Plasminogen Activator Receptor (uPAR), Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR) are three biomarkers that exhibit enhanced expression in many types of cancers, and have been investigated as potential biomarkers for targeted strategies and prognostication. The aim of the study was to investigate the expression patterns of uPAR, TF and EGFR and their potential prognostic value in OSCC. Methods: Immunohistochemical expression of uPAR, TF and EGFR in tumor resection specimens from 191 patients with primary OSCC was analyzed. Overall (OS) and disease-free survival (DFS) was calculated. Associations between biomarker expression, clinicopathological factors and patient survival was analyzed using the Cox proportional hazards model for univariate and multivariate analysis, log rank and Kaplan-Meier statistics. Results: uPAR and TF exhibited a highly tumor-specific expression pattern while EGFR also showed expression in normal tissues outside the tumor compartment. The overall positive expression rate of uPAR, TF and EGFR was 95{\%}, 58{\%} and 98{\%}, respectively. High uPAR expression across the entire cohort was negatively associated with OS (p=0.031, HR=1.595 (95{\%}CI 1.044-2.439)) in univariate analysis. The 5-year OS for high and low uPAR expression was 39{\%} and 56{\%}, respectively. The expression of TF and EGFR was not associated with survival outcome. Conclusions: This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. uPAR seems to be a prognostic biomarker in oral cancer.",
keywords = "EGFR, Immunohistochemistry, Margins, Molecular imaging, Oral cancer, Oral squamous cell carcinoma, Prognosis, Tissue factor, UPAR",
author = "Anders Christensen and Katalin Kiss and Giedrius Lelkaitis and Karina Juhl and Morten Persson and Charabi, {Birgitte Wittenborg} and Jann Mortensen and Forman, {Julie Lyng} and S{\o}rensen, {Anne Lyngholm} and Jensen, {David Hebbelstrup} and Andreas Kjaer and {von Buchwald}, Christian",
year = "2017",
doi = "10.1186/s12885-017-3563-3",
language = "English",
volume = "17",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR)

T2 - tumor expression patterns and prognostic value in oral cancer

AU - Christensen, Anders

AU - Kiss, Katalin

AU - Lelkaitis, Giedrius

AU - Juhl, Karina

AU - Persson, Morten

AU - Charabi, Birgitte Wittenborg

AU - Mortensen, Jann

AU - Forman, Julie Lyng

AU - Sørensen, Anne Lyngholm

AU - Jensen, David Hebbelstrup

AU - Kjaer, Andreas

AU - von Buchwald, Christian

PY - 2017

Y1 - 2017

N2 - Background: Tumor-specific biomarkers are a prerequisite for the development of targeted imaging and therapy in oral squamous cell carcinoma (OSCC). urokinase-type Plasminogen Activator Receptor (uPAR), Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR) are three biomarkers that exhibit enhanced expression in many types of cancers, and have been investigated as potential biomarkers for targeted strategies and prognostication. The aim of the study was to investigate the expression patterns of uPAR, TF and EGFR and their potential prognostic value in OSCC. Methods: Immunohistochemical expression of uPAR, TF and EGFR in tumor resection specimens from 191 patients with primary OSCC was analyzed. Overall (OS) and disease-free survival (DFS) was calculated. Associations between biomarker expression, clinicopathological factors and patient survival was analyzed using the Cox proportional hazards model for univariate and multivariate analysis, log rank and Kaplan-Meier statistics. Results: uPAR and TF exhibited a highly tumor-specific expression pattern while EGFR also showed expression in normal tissues outside the tumor compartment. The overall positive expression rate of uPAR, TF and EGFR was 95%, 58% and 98%, respectively. High uPAR expression across the entire cohort was negatively associated with OS (p=0.031, HR=1.595 (95%CI 1.044-2.439)) in univariate analysis. The 5-year OS for high and low uPAR expression was 39% and 56%, respectively. The expression of TF and EGFR was not associated with survival outcome. Conclusions: This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. uPAR seems to be a prognostic biomarker in oral cancer.

AB - Background: Tumor-specific biomarkers are a prerequisite for the development of targeted imaging and therapy in oral squamous cell carcinoma (OSCC). urokinase-type Plasminogen Activator Receptor (uPAR), Tissue Factor (TF) and Epidermal Growth Factor Receptor (EGFR) are three biomarkers that exhibit enhanced expression in many types of cancers, and have been investigated as potential biomarkers for targeted strategies and prognostication. The aim of the study was to investigate the expression patterns of uPAR, TF and EGFR and their potential prognostic value in OSCC. Methods: Immunohistochemical expression of uPAR, TF and EGFR in tumor resection specimens from 191 patients with primary OSCC was analyzed. Overall (OS) and disease-free survival (DFS) was calculated. Associations between biomarker expression, clinicopathological factors and patient survival was analyzed using the Cox proportional hazards model for univariate and multivariate analysis, log rank and Kaplan-Meier statistics. Results: uPAR and TF exhibited a highly tumor-specific expression pattern while EGFR also showed expression in normal tissues outside the tumor compartment. The overall positive expression rate of uPAR, TF and EGFR was 95%, 58% and 98%, respectively. High uPAR expression across the entire cohort was negatively associated with OS (p=0.031, HR=1.595 (95%CI 1.044-2.439)) in univariate analysis. The 5-year OS for high and low uPAR expression was 39% and 56%, respectively. The expression of TF and EGFR was not associated with survival outcome. Conclusions: This study may suggest that uPAR and TF could potentially be attractive targets for molecular imaging and therapy in OSCC due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. uPAR seems to be a prognostic biomarker in oral cancer.

KW - EGFR

KW - Immunohistochemistry

KW - Margins

KW - Molecular imaging

KW - Oral cancer

KW - Oral squamous cell carcinoma

KW - Prognosis

KW - Tissue factor

KW - UPAR

U2 - 10.1186/s12885-017-3563-3

DO - 10.1186/s12885-017-3563-3

M3 - Journal article

VL - 17

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

M1 - 572

ER -

ID: 188963010